The present invention extends to the compound of formula I: or a prodrug, pharmaceutically acceptable salt, or solvate of said compound. Furthermore, the present invention is directed to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula I, and a pharmaceutically acceptable carrier. Furthermore, the present invention is directed to the use of a compound of formula I as an inhibitor of tryptase, comprising introducing the compound into a composition comprising tryptase. In addition, the present invention is directed to the use of a compound of formula I for treating a patient suffering from, or subject to, a physiological condition in need of amelioration of an inhibitor of tryptase comprising administering to the patient a therapeutically effective amount of the compound of Claim 1. The present invention is directed also to the preparation of a compound of formula I.
本发明涉及到式I的化合物:或者该化合物的前药、药用可接受的盐或溶剂。此外,本发明涉及一种包括式I化合物的药物组合物,以及药用可接受的载体的药学有效量。此外,本发明涉及将式I化合物用作色
氨酸
蛋白酶抑制剂的用途,包括将该化合物引入含有色
氨酸
蛋白酶的组合物中。此外,本发明还涉及将式I化合物用于治疗患有或患有需要改善色
氨酸
蛋白酶抑制剂的生理状况的患者的用途,包括向患者施用权利要求1中的化合物的治疗有效量。本发明还涉及制备式I化合物。